Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Sofia Heigis presents at Biostock

March 5, 2026 – Sofia Heigis, CEO of Oncopeptides, recently visited the Biostock studio to present the company, its’ ambitions for Pepaxti in Europe and rest of the world and also outline the company´s strategic pivot into a multi-indication global biotech, spearheaded by its glioblastoma project.

Watch the interview

Oncopeptides carries out a rights issue of approximately SEK 200 million

The Rights Issue is being carried out to strengthen the Company’s financial position, provide additional scope for the ongoing commercialization of Pepaxti in Europe, and advance the Company’s preclinical project for the indication glioblastoma to the clinical development phase.

Find all information about the rights issue here

CEO Sofia Heigis - Oncopeptides AB

Released February 19, 2026

Oncopeptides publishes year-end report 2025

Read report

Download

“Net sales more than doubled in 2025 with 125 percent growth, as glioblastoma program marks strategic pipeline expansion beyond multiple myeloma”

CEO Sofia Heigis

 

See the Webcast

 

 

For further information, please contact:

David Augustsson
Director of IR and Communications
ir@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2026 will be published May 13, 2026

Company news

Notice to Annual General Meeting at Oncopeptides AB (publ)

April 16, 2025

The shareholders in Oncopeptides AB are hereby given notice to attend the Annual General Meeting to be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 22 May 2025 at 10.00 a.m.

Read more

Oncopeptalks – first order in Italy and Q4 report

March 13, 2025

In the latest episode of Oncopeptalks, David and Sofia discuss the recent news of a first Pepaxti order in Italy and some of the questions following the Q4 report.

Read more

Oncopeptides receives first order of Pepaxti in Italy

March 11, 2025

Read more

Science news

Research shows that Pepaxti is effective in high-risk myeloma

December 31, 2025

Oncopeptides recently announced new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations.

Read more

NKEngage Grant Project Completed

November 12, 2025

The NKEngage project, funded under the Eurostars program (Vinnova/Eureka), has successfully concluded after achieving its research goals.

Read more

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

November 11, 2025

Oncopeptides today announced that a panel of leading multiple myeloma experts has published clinical recommendations for the optimal use of melflufen (branded in Europe as Pepaxti) in Annals of Hematology.

Read more

Investor news

Sofia Heigis presents at Biostock

March 5, 2026

Read more

Oncopeptalks about the Q4 report 2025, rights issue and pipeline news

February 23, 2026

Read more
Sofia Heigis på Redeye 19 februari 2026

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

February 20, 2026

Redeye analyst Richard Remanius recently interviewed CEO Sofia Heigis about Q4 and the upcoming new share issue of approximately SEK 200 million.

Read more

All Company news

All Science news

All Investor news

Press release - February 26, 2026

Oncopeptides publishes disclosure document regarding rights issue

Read press release

Latest press releases

All press releases

Upcoming events

2026-04-13 - 2026-05-12

Silent period

Other

2026-05-13

Interim Report Q1 2026

Report

2026-05-21

Annual General Meeting 2026

Meeting

Full calendar
Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.

Read more about our history

Released April 28, 2025

Oncopeptides publishes the 2024 Annual Report

Read report

Download

“2024 was a transformative year for Oncopeptides as we continued our journey toward sustainable growth and expanded access to Pepaxti.”

CEO Sofia Heigis

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Interim Report Q1 2025 will be published May 15, 2025

Oncopeptides via e-mail